BACKGROUND: Maturity-onset diabetes of the young (MODY) is an antibody-negative, autosomal dominant form of diabetes. With the increasing prevalence of diabetes and the expense of MODY testing, markers to identify those who need further genetic testing would be beneficial. We investigated whether HLA genotypes, random C-peptide, and/or high-sensitivity C-reactive protein (hsCRP) levels could be helpful biomarkers for identifying MODY in antibody-negative diabetes. METHODS: Subjects (N = 97) with diabetes onset ≤age 25, measurable C-peptide (≥0.1 ng/mL), and negative for all four diabetes autoantibodies were enrolled at a large academic center and tested for MODY 1-5 through Athena Diagnostics. A total of 22 subjects had a positive or very likely pathogenic mutation for MODY. RESULTS: Random C-peptide levels were significantly different between MODY-positive and MODY-negative subjects (0.16 nmol/L vs. 0.02 nmol/L; P = 0.02). After adjusting for age and diabetes duration, hsCRP levels were significantly lower in MODY-positive subjects (0.37 mg/L vs. 0.87 mg/L; P = 0.02). Random C-peptide level ≥0.15 nmol/L obtained at ≥6 months after diagnosis had 83% sensitivity for diagnosis of MODY with a negative predictive value of 96%. Receiver operating characteristic curves showed that area under the curve for random C-peptide (0.75) was significantly better than hsCRP (0.54), high-risk HLA DR3/4-DQB1*0302 (0.59), and high-risk HLA/random C-peptide combined (0.54; P = 0.03). CONCLUSIONS: Random C-peptide obtained at ≥6 months after diagnosis can be a useful biomarker to identify antibody-negative individuals who need further genetic testing for MODY, whereas hsCRP and HLA do not appear to improve this antibody/C-peptide-based approach.
BACKGROUND: Maturity-onset diabetes of the young (MODY) is an antibody-negative, autosomal dominant form of diabetes. With the increasing prevalence of diabetes and the expense of MODY testing, markers to identify those who need further genetic testing would be beneficial. We investigated whether HLA genotypes, random C-peptide, and/or high-sensitivity C-reactive protein (hsCRP) levels could be helpful biomarkers for identifying MODY in antibody-negative diabetes. METHODS: Subjects (N = 97) with diabetes onset ≤age 25, measurable C-peptide (≥0.1 ng/mL), and negative for all four diabetes autoantibodies were enrolled at a large academic center and tested for MODY 1-5 through Athena Diagnostics. A total of 22 subjects had a positive or very likely pathogenic mutation for MODY. RESULTS: Random C-peptide levels were significantly different between MODY-positive and MODY-negative subjects (0.16 nmol/L vs. 0.02 nmol/L; P = 0.02). After adjusting for age and diabetes duration, hsCRP levels were significantly lower in MODY-positive subjects (0.37 mg/L vs. 0.87 mg/L; P = 0.02). Random C-peptide level ≥0.15 nmol/L obtained at ≥6 months after diagnosis had 83% sensitivity for diagnosis of MODY with a negative predictive value of 96%. Receiver operating characteristic curves showed that area under the curve for random C-peptide (0.75) was significantly better than hsCRP (0.54), high-risk HLA DR3/4-DQB1*0302 (0.59), and high-risk HLA/random C-peptide combined (0.54; P = 0.03). CONCLUSIONS: Random C-peptide obtained at ≥6 months after diagnosis can be a useful biomarker to identify antibody-negative individuals who need further genetic testing for MODY, whereas hsCRP and HLA do not appear to improve this antibody/C-peptide-based approach.
Entities:
Keywords:
Biomarkers.; GCK; HNF1A; HNF4A; Maturity-onset diabetes of the young
Authors: Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: G Thanabalasingham; N Shah; M Vaxillaire; T Hansen; T Tuomi; D Gašperíková; M Szopa; E Tjora; T J James; P Kokko; F Loiseleur; E Andersson; S Gaget; B Isomaa; N Nowak; H Raeder; J Stanik; P R Njolstad; M T Malecki; I Klimes; L Groop; O Pedersen; P Froguel; M I McCarthy; A L Gloyn; K R Owen Journal: Diabetologia Date: 2011-08-04 Impact factor: 10.122
Authors: M N Weedon; A T Hattersley; K A Patel; R A Oram; S E Flanagan; E De Franco; K Colclough; M Shepherd; S Ellard Journal: Diabetes Date: 2016-04-05 Impact factor: 9.461
Authors: Paturi V Rao; Eric Bean; Dhanalakshmi Nair-Schaef; Siting Chen; Steven C Kazmierczak; Charles T Roberts; Srinivasa R Nagalla Journal: J Diabetes Sci Technol Date: 2021-03-17
Authors: Magdalena Szopa; Tomasz Klupa; Maria Kapusta; Bartlomiej Matejko; Damian Ucieklak; Wojciech Glodzik; Barbara Zapala; Cyrus Maurice Sani; Jerzy Hohendorff; Maciej T Malecki; Jan Skupien Journal: Endocrine Date: 2019-02-18 Impact factor: 3.633
Authors: Thu T Tran; Vijay G Linga; Mohammed A I Al-Obaide; Daniella Bello-Germino; Mehar Hoda; Olubukunola Adesanya; Tetyana L Vasylyeva Journal: Biomed Rep Date: 2021-11-16